Inozyme Pharma, Inc. (NASDAQ:INZY) – Research analysts at Piper Sandler upped their Q2 2021 EPS estimates for shares of Inozyme Pharma in a report released on Wednesday, May 12th. Piper Sandler analyst C. Raymond now expects that the company will post earnings per share of ($0.56) for the quarter, up from their prior forecast of ($0.60). Piper Sandler also issued estimates for Inozyme Pharma’s Q3 2021 earnings at ($0.65) EPS, FY2021 earnings at ($2.41) EPS, Q3 2022 earnings at ($0.71) EPS and FY2022 earnings at ($2.81) EPS.
Inozyme Pharma (NASDAQ:INZY) last issued its earnings results on Wednesday, May 12th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.07.
Several institutional investors have recently bought and sold shares of INZY. Morgan Stanley bought a new position in shares of Inozyme Pharma during the 3rd quarter worth approximately $33,000. State of Wisconsin Investment Board bought a new position in shares of Inozyme Pharma during the 4th quarter worth approximately $235,000. BlackRock Inc. lifted its position in shares of Inozyme Pharma by 25.9% during the 4th quarter. BlackRock Inc. now owns 630,751 shares of the company’s stock worth $13,018,000 after buying an additional 129,817 shares in the last quarter. New York State Common Retirement Fund bought a new stake in shares of Inozyme Pharma in the 4th quarter worth approximately $153,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Inozyme Pharma by 10.1% in the 4th quarter. Bank of New York Mellon Corp now owns 21,349 shares of the company’s stock worth $440,000 after purchasing an additional 1,964 shares during the period. 69.77% of the stock is currently owned by hedge funds and other institutional investors.
Inozyme Pharma Company Profile
Inozyme Pharma, Inc, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.
Featured Article: Initial Public Offering (IPO)
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.